Chinese General Practice ›› 2022, Vol. 25 ›› Issue (17): 2126-2134.DOI: 10.12114/j.issn.1007-9572.2021.02.007
Special Issue: 社区卫生服务最新研究合集; 消化系统疾病最新文章合集
• Article • Previous Articles Next Articles
Received:
2021-05-23
Revised:
2021-10-27
Published:
2022-04-22
Online:
2022-04-22
Contact:
Jilin MA
About author:
通讯作者:
马纪林
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.007
组别 | 例数 | 女性〔n(%)〕 | 年龄( | BMI(kg/m2) | 腰围( | 臀围( | 腰臀比( | 收缩压( | 舒张压( | 空腹血糖( | 总胆固醇( | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
健康对照组 | 1 075 | 737(68.56) | 59.5±9.2 | 22.2±2.6 | 74.5±7.6 | 88.5±5.1 | 0.84±0.06 | 118±11 | 77±7 | 5.3±0.5 | 4.70±0.70 | |
对照组 | 1 948 | 1 083(55.60)a | 64.7±9.0a | 23.4±2.6a | 79.1±7.8a | 90.6±5.4 | 0.87±0.06a | 140±17a | 86±10a | 6.0±1.6a | 4.94±1.04 | |
NAFLD组 | 1 248 | 1 045(83.73)ab | 63.2±7.8ab | 26.1±3.0ab | 83.7±7.6ab | 94.0±5.8 | 0.89±0.05ab | 139±17a | 85±9a | 6.0±1.4a | 5.21±1.05 | |
MAFLD组 | 1 456 | 995(68.34)bc | 64.7±8.3ac | 27.9±3.0abc | 90.2±7.8abc | 97.3±6.3 | 0.93±0.05abc | 142±18abc | 86±10a | 7.4±2.5abc | 5.18±1.13 | |
检验统计量值 | 96.707 | 98.774 | 1 137.694 | 1 005.658 | 631.238 | 573.261 | 557.742 | 255.693 | 357.480 | 65.384 | ||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
组别 | 三酰甘油( | LDL-C( | HLD-C( | 总胆红素( | 血尿酸( | ALT( | AST( | ALT/AST( | GGT〔M(QR),U/L〕 | eGFR〔 | 白细胞计数( | |
健康对照组 | 1.10±0.40 | 2.96±0.63 | 1.60±0.34 | 12.33±6.10 | 281.73±68.59 | 16±13 | 21±8 | 0.74±0.25 | 14.95(22.56) | 90.91±13.05 | 5.5±1.3 | |
对照组 | 1.44±0.96a | 3.18±0.96 | 1.48±0.38a | 12.47±5.38 | 310.08±81.23a | 17±11a | 21±8 | 0.79±0.27a | 18.67(28.44) | 85.60±14.81a | 5.9±1.5a | |
NAFLD组 | 1.76±0.92ab | 3.46±0.96 | 1.38±0.28ab | 12.02±5.04 | 327.10±76.86ab | 26±19ab | 24±12ab | 1.03±0.34ab | 24.55(37.01) | 88.62±12.45ab | 6.1±1.4ab | |
MAFLD组 | 2.66±1.72abc | 3.29±1.03 | 1.17±0.27abc | 11.99±4.78 | 351.50±84.15abc | 31±23abc | 26±14abc | 1.14±0.36abc | 30.40(46.71) | 86.25±14.62ac | 6.6±1.6abc | |
检验统计量值 | 479.960 | 59.596 | 411.073 | 3.136 | 175.232 | 268.532 | 83.674 | 541.209 | 78.484e | 39.971 | 141.461 | |
P值 | <0.001 | <0.001 | <0.001 | 0.024 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | 中性粒细胞计数( | 单核细胞计数( | 淋巴细胞计数( | 血小板计数( | NLR( | PLR( | LMR( | MHR( | ANI〔M(QR)〕 | LAP( | AIP( | |
健康对照组 | 3.2±1.1 | 0.3±0.1 | 1.8±0.5 | 220.1±59.0 | 0.23±0.10 | 130.06±44.65 | 1.90±0.94 | 0.20±0.09 | 130.06±44.65 | 16.24±10.96 | -0.18±0.21 | |
对照组 | 3.5±1.2a | 0.4±0.2a | 1.9±0.6a | 222.7±62.9 | 0.29±0.15a | 125.62±46.16a | 1.99±1.04a | 0.22±0.09a | 125.62±46.16a | 26.75±21.82a | -0.05±0.28a | |
NAFLD组 | 3.5±1.1a | 0.4±0.1ab | 2.1±0.6ab | 236.5±58.7ab | 0.29±0.11a | 120.35±40.29ab | 1.79±0.70ab | 0.20±0.07ab | 120.35±40.29ab | 41.70±21.28ab | 0.07±0.23ab | |
MAFLD组 | 3.8±1.1abc | 0.4±0.1abc | 2.2±0.7abc | 234.8±64.3ab | 0.39±0.16abc | 113.80±40.36abc | 1.86±0.76bc | 0.21±0.08bc | 113.80±40.36abc | 77.62±49.89abc | 0.31±0.27abc | |
检验统计量值 | 72.693 | 84.465 | 119.124 | 24.379 | 298.825 | 35.014 | 13.422 | 29.055 | 35.014e | 1 094.515 | 914.337 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | 腰围分类〔n(%)〕 | BMI分类〔n(%)〕 | 高血压〔n(%)〕 | 血脂异常〔n(%)〕 | ||||||||
≥90 cm(男)或≥85 cm(女) | <90 cm(男)或<85 cm(女) | 正常 | 超重 | 肥胖 | 无 | 有 | 无 | 高胆固醇血症 | 高三酰甘油血症 | 混合性高脂血症 | 低高密度脂蛋白血症 | |
健康对照组 | 58(5.40) | 1 017(94.60) | 741(68.93) | 220(20.47) | 114(10.60) | 1 075(100.00) | 0 | 1 075(100.00) | 0 | 0 | 0 | 0 |
对照组 | 264(13.55) | 1 684(86.45) | 1 087(55.80) | 690(35.42) | 171(8.78) | 146(7.49) | 1 802(92.51) | 1 475(75.72) | 173(8.88) | 172(8.83) | 35(1.80) | 93(4.77) |
NAFLD组 | 380(30.45) | 868(69.55) | 267(21.39) | 666(53.37) | 315(25.24) | 211(16.91) | 1 037(83.09) | 850(68.11) | 131(10.50) | 178(14.26) | 66(5.29) | 23(1.84) |
MAFLD组 | 1 104(75.82) | 352(24.18) | 122(8.38) | 653(44.85) | 681(46.77) | 153(10.51) | 1 303(89.49) | 545(37.43) | 109(7.49) | 524(35.99) | 136(9.34) | 142(9.75) |
检验统计量值 | 1 955.472d | 1 975.670d | 3 492.297d | 1 435.230d | ||||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 1 Comparison of general information,anthropometric indicators,blood pressure,biochemical indicators and routine blood test results between physical examinees without metabolic disorders,those with other metabolic disorders except nonalcoholic fatty liver disease and metabolic syndrome,those with nonalcoholic fatty liver disease,and those with both nonalcoholic fatty liver disease and metabolic syndrome
组别 | 例数 | 女性〔n(%)〕 | 年龄( | BMI(kg/m2) | 腰围( | 臀围( | 腰臀比( | 收缩压( | 舒张压( | 空腹血糖( | 总胆固醇( | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
健康对照组 | 1 075 | 737(68.56) | 59.5±9.2 | 22.2±2.6 | 74.5±7.6 | 88.5±5.1 | 0.84±0.06 | 118±11 | 77±7 | 5.3±0.5 | 4.70±0.70 | |
对照组 | 1 948 | 1 083(55.60)a | 64.7±9.0a | 23.4±2.6a | 79.1±7.8a | 90.6±5.4 | 0.87±0.06a | 140±17a | 86±10a | 6.0±1.6a | 4.94±1.04 | |
NAFLD组 | 1 248 | 1 045(83.73)ab | 63.2±7.8ab | 26.1±3.0ab | 83.7±7.6ab | 94.0±5.8 | 0.89±0.05ab | 139±17a | 85±9a | 6.0±1.4a | 5.21±1.05 | |
MAFLD组 | 1 456 | 995(68.34)bc | 64.7±8.3ac | 27.9±3.0abc | 90.2±7.8abc | 97.3±6.3 | 0.93±0.05abc | 142±18abc | 86±10a | 7.4±2.5abc | 5.18±1.13 | |
检验统计量值 | 96.707 | 98.774 | 1 137.694 | 1 005.658 | 631.238 | 573.261 | 557.742 | 255.693 | 357.480 | 65.384 | ||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
组别 | 三酰甘油( | LDL-C( | HLD-C( | 总胆红素( | 血尿酸( | ALT( | AST( | ALT/AST( | GGT〔M(QR),U/L〕 | eGFR〔 | 白细胞计数( | |
健康对照组 | 1.10±0.40 | 2.96±0.63 | 1.60±0.34 | 12.33±6.10 | 281.73±68.59 | 16±13 | 21±8 | 0.74±0.25 | 14.95(22.56) | 90.91±13.05 | 5.5±1.3 | |
对照组 | 1.44±0.96a | 3.18±0.96 | 1.48±0.38a | 12.47±5.38 | 310.08±81.23a | 17±11a | 21±8 | 0.79±0.27a | 18.67(28.44) | 85.60±14.81a | 5.9±1.5a | |
NAFLD组 | 1.76±0.92ab | 3.46±0.96 | 1.38±0.28ab | 12.02±5.04 | 327.10±76.86ab | 26±19ab | 24±12ab | 1.03±0.34ab | 24.55(37.01) | 88.62±12.45ab | 6.1±1.4ab | |
MAFLD组 | 2.66±1.72abc | 3.29±1.03 | 1.17±0.27abc | 11.99±4.78 | 351.50±84.15abc | 31±23abc | 26±14abc | 1.14±0.36abc | 30.40(46.71) | 86.25±14.62ac | 6.6±1.6abc | |
检验统计量值 | 479.960 | 59.596 | 411.073 | 3.136 | 175.232 | 268.532 | 83.674 | 541.209 | 78.484e | 39.971 | 141.461 | |
P值 | <0.001 | <0.001 | <0.001 | 0.024 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | 中性粒细胞计数( | 单核细胞计数( | 淋巴细胞计数( | 血小板计数( | NLR( | PLR( | LMR( | MHR( | ANI〔M(QR)〕 | LAP( | AIP( | |
健康对照组 | 3.2±1.1 | 0.3±0.1 | 1.8±0.5 | 220.1±59.0 | 0.23±0.10 | 130.06±44.65 | 1.90±0.94 | 0.20±0.09 | 130.06±44.65 | 16.24±10.96 | -0.18±0.21 | |
对照组 | 3.5±1.2a | 0.4±0.2a | 1.9±0.6a | 222.7±62.9 | 0.29±0.15a | 125.62±46.16a | 1.99±1.04a | 0.22±0.09a | 125.62±46.16a | 26.75±21.82a | -0.05±0.28a | |
NAFLD组 | 3.5±1.1a | 0.4±0.1ab | 2.1±0.6ab | 236.5±58.7ab | 0.29±0.11a | 120.35±40.29ab | 1.79±0.70ab | 0.20±0.07ab | 120.35±40.29ab | 41.70±21.28ab | 0.07±0.23ab | |
MAFLD组 | 3.8±1.1abc | 0.4±0.1abc | 2.2±0.7abc | 234.8±64.3ab | 0.39±0.16abc | 113.80±40.36abc | 1.86±0.76bc | 0.21±0.08bc | 113.80±40.36abc | 77.62±49.89abc | 0.31±0.27abc | |
检验统计量值 | 72.693 | 84.465 | 119.124 | 24.379 | 298.825 | 35.014 | 13.422 | 29.055 | 35.014e | 1 094.515 | 914.337 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | 腰围分类〔n(%)〕 | BMI分类〔n(%)〕 | 高血压〔n(%)〕 | 血脂异常〔n(%)〕 | ||||||||
≥90 cm(男)或≥85 cm(女) | <90 cm(男)或<85 cm(女) | 正常 | 超重 | 肥胖 | 无 | 有 | 无 | 高胆固醇血症 | 高三酰甘油血症 | 混合性高脂血症 | 低高密度脂蛋白血症 | |
健康对照组 | 58(5.40) | 1 017(94.60) | 741(68.93) | 220(20.47) | 114(10.60) | 1 075(100.00) | 0 | 1 075(100.00) | 0 | 0 | 0 | 0 |
对照组 | 264(13.55) | 1 684(86.45) | 1 087(55.80) | 690(35.42) | 171(8.78) | 146(7.49) | 1 802(92.51) | 1 475(75.72) | 173(8.88) | 172(8.83) | 35(1.80) | 93(4.77) |
NAFLD组 | 380(30.45) | 868(69.55) | 267(21.39) | 666(53.37) | 315(25.24) | 211(16.91) | 1 037(83.09) | 850(68.11) | 131(10.50) | 178(14.26) | 66(5.29) | 23(1.84) |
MAFLD组 | 1 104(75.82) | 352(24.18) | 122(8.38) | 653(44.85) | 681(46.77) | 153(10.51) | 1 303(89.49) | 545(37.43) | 109(7.49) | 524(35.99) | 136(9.34) | 142(9.75) |
检验统计量值 | 1 955.472d | 1 975.670d | 3 492.297d | 1 435.230d | ||||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
Figure 3 ROC analysis for noninvasive indicators(including neutrophil to lymphocyte ratio,platelet to lymphocyte ratio,lymphocyte to monocyte ratio and monocyte to high-density lipoprotein cholesterol ratio)in predicting nonalcoholic fatty liver disease with metabolic syndrome in physical examinees in the community
项目 | MHR≤0.292(n=2 350) | MHR>0.292(n=2 302) | 检验统计量值 | P值 | 项目 | MHR≤0.292(n=2 350) | MHR>0.292(n=2 302) | 检验统计量值 | P值 | |
---|---|---|---|---|---|---|---|---|---|---|
性别(男/女) | 455/1 905 | 1 084/1 218 | 417.727a | <0.001 | PLR( | 126.88±43.84 | 114.00±41.44 | 105.961 | <0.001 | |
年龄( | 63.5±8.2 | 65.1±8.7 | 6.504 | <0.001 | LMR( | 0.18±0.06 | 0.24±0.09 | 657.565 | <0.001 | |
BMI( | 24.8±3.4 | 26.2±3.4 | 14.623 | <0.001 | ANI〔M(QR)〕 | -2.94(0.22) | -2.45(0.97) | 1.351b | 0.245 | |
腰围( | 81.0±8.5 | 86.7±8.7 | 22.600 | <0.001 | LAP( | 35.75±26.48 | 57.86±47.07 | 19.792 | <0.001 | |
臀围( | 92.1±6.2 | 95.1±6.4 | 253.068 | <0.001 | AIP( | -0.03±0.27 | 0.22±0.29 | 30.217 | <0.001 | |
腰臀比( | 0.88±0.06 | 0.91±0.06 | 20.016 | <0.001 | 腰围分类〔n(%)〕 | 169.495 | <0.001 | |||
收缩压( | 141±17 | 140±18 | 1.837 | 0.066 | ≥90 cm(男)或≥85 cm(女) | 668(28.43) | 1 080(46.92) | |||
舒张压( | 86±9 | 86±10 | 1.152 | 0.249 | <90 cm(男)或<85 cm(女) | 1 682(71.57) | 1 222(53.08) | |||
空腹血糖( | 6.2±1.7 | 6.7±2.2 | 9.522 | <0.001 | BMI分类 | 161.870a | <0.001 | |||
总胆固醇( | 5.22±1.05 | 4.94±1.09 | 8.854 | <0.001 | 正常 | 913(38.85) | 563(24.46) | |||
三酰甘油( | 1.58±0.87 | 2.24±1.63 | 17.348 | <0.001 | 超重 | 961(40.89) | 1 048(45.53) | |||
LDL-C( | 3.39±0.99 | 3.18±0.97 | 7.223 | <0.001 | 肥胖 | 476(20.26) | 691(30.01) | |||
HDL-C( | 1.53±0.34 | 1.18±0.25 | 40.574 | <0.001 | 高血压 | 5.788a | <0.001 | |||
总胆红素( | 12.16±5.22 | 12.24±5.01 | 0.234 | 0.629 | 无 | 232(9.87) | 278(12.08) | |||
血尿酸( | 304.45±73.32 | 351.25±85.38 | 20.072 | <0.001 | 有 | 2 118(90.13) | 2 024(87.92) | |||
ALT( | 21±16 | 27±20 | 10.371 | <0.001 | 血脂异常〔n(%)〕 | 457.264a | <0.001 | |||
AST( | 23±11 | 25±12 | 5.240 | <0.001 | 无 | 1 687(71.79) | 1 183(51.39) | |||
ALT/AST | 0.88±0.32 | 1.04±0.37 | 15.191 | <0.001 | 高胆固醇血症 | 285(12.13) | 128(5.56) | |||
GGT〔M(QR),U/L〕 | 20.17(31.60) | 24.47(41.19) | 56.332b | <0.001 | 高三酰甘油血症 | 256(10.89) | 618(26.85) | |||
eGFR〔 | 88.35±13.13 | 84.84±15.02 | 8.494 | <0.001 | 混合性高脂血症 | 90(3.83) | 147(6.39) | |||
白细胞计数( | 5.5±1.1 | 6.9±1.5 | 35.590 | <0.001 | 低高密度脂蛋白血症 | 32(1.36) | 226(9.81) | |||
中性粒细胞计数( | 3.2±0.9 | 4.0±1.2 | 25.921 | <0.001 | 分组〔n(%)〕 | 341.805a | <0.001 | |||
单核细胞计数( | 0.3±0.1 | 0.5±0.1 | 55.544 | <0.001 | 对照组 | 1 181(50.26) | 767(33.32) | |||
淋巴细胞计数( | 1.9±0.6 | 2.2±0.7 | 19.815 | <0.001 | NAFLD组 | 725(30.85) | 523(22.72) | |||
血小板计数( | 223.2±59.4 | 237.3±64.9 | 7.740 | <0.001 | MAFLD组 | 444(18.89) | 1 012(43.96) | |||
NLR( | 1.84±0.75 | 1.95±0.99 | 20.166 | <0.001 |
Table 2 Comparison of general information,anthropometric indicators,blood pressure,biochemical indicators,routine blood test results in physical examinees with target metabolic disorders by monocyte to high-density lipoprotein cholesterol ratio
项目 | MHR≤0.292(n=2 350) | MHR>0.292(n=2 302) | 检验统计量值 | P值 | 项目 | MHR≤0.292(n=2 350) | MHR>0.292(n=2 302) | 检验统计量值 | P值 | |
---|---|---|---|---|---|---|---|---|---|---|
性别(男/女) | 455/1 905 | 1 084/1 218 | 417.727a | <0.001 | PLR( | 126.88±43.84 | 114.00±41.44 | 105.961 | <0.001 | |
年龄( | 63.5±8.2 | 65.1±8.7 | 6.504 | <0.001 | LMR( | 0.18±0.06 | 0.24±0.09 | 657.565 | <0.001 | |
BMI( | 24.8±3.4 | 26.2±3.4 | 14.623 | <0.001 | ANI〔M(QR)〕 | -2.94(0.22) | -2.45(0.97) | 1.351b | 0.245 | |
腰围( | 81.0±8.5 | 86.7±8.7 | 22.600 | <0.001 | LAP( | 35.75±26.48 | 57.86±47.07 | 19.792 | <0.001 | |
臀围( | 92.1±6.2 | 95.1±6.4 | 253.068 | <0.001 | AIP( | -0.03±0.27 | 0.22±0.29 | 30.217 | <0.001 | |
腰臀比( | 0.88±0.06 | 0.91±0.06 | 20.016 | <0.001 | 腰围分类〔n(%)〕 | 169.495 | <0.001 | |||
收缩压( | 141±17 | 140±18 | 1.837 | 0.066 | ≥90 cm(男)或≥85 cm(女) | 668(28.43) | 1 080(46.92) | |||
舒张压( | 86±9 | 86±10 | 1.152 | 0.249 | <90 cm(男)或<85 cm(女) | 1 682(71.57) | 1 222(53.08) | |||
空腹血糖( | 6.2±1.7 | 6.7±2.2 | 9.522 | <0.001 | BMI分类 | 161.870a | <0.001 | |||
总胆固醇( | 5.22±1.05 | 4.94±1.09 | 8.854 | <0.001 | 正常 | 913(38.85) | 563(24.46) | |||
三酰甘油( | 1.58±0.87 | 2.24±1.63 | 17.348 | <0.001 | 超重 | 961(40.89) | 1 048(45.53) | |||
LDL-C( | 3.39±0.99 | 3.18±0.97 | 7.223 | <0.001 | 肥胖 | 476(20.26) | 691(30.01) | |||
HDL-C( | 1.53±0.34 | 1.18±0.25 | 40.574 | <0.001 | 高血压 | 5.788a | <0.001 | |||
总胆红素( | 12.16±5.22 | 12.24±5.01 | 0.234 | 0.629 | 无 | 232(9.87) | 278(12.08) | |||
血尿酸( | 304.45±73.32 | 351.25±85.38 | 20.072 | <0.001 | 有 | 2 118(90.13) | 2 024(87.92) | |||
ALT( | 21±16 | 27±20 | 10.371 | <0.001 | 血脂异常〔n(%)〕 | 457.264a | <0.001 | |||
AST( | 23±11 | 25±12 | 5.240 | <0.001 | 无 | 1 687(71.79) | 1 183(51.39) | |||
ALT/AST | 0.88±0.32 | 1.04±0.37 | 15.191 | <0.001 | 高胆固醇血症 | 285(12.13) | 128(5.56) | |||
GGT〔M(QR),U/L〕 | 20.17(31.60) | 24.47(41.19) | 56.332b | <0.001 | 高三酰甘油血症 | 256(10.89) | 618(26.85) | |||
eGFR〔 | 88.35±13.13 | 84.84±15.02 | 8.494 | <0.001 | 混合性高脂血症 | 90(3.83) | 147(6.39) | |||
白细胞计数( | 5.5±1.1 | 6.9±1.5 | 35.590 | <0.001 | 低高密度脂蛋白血症 | 32(1.36) | 226(9.81) | |||
中性粒细胞计数( | 3.2±0.9 | 4.0±1.2 | 25.921 | <0.001 | 分组〔n(%)〕 | 341.805a | <0.001 | |||
单核细胞计数( | 0.3±0.1 | 0.5±0.1 | 55.544 | <0.001 | 对照组 | 1 181(50.26) | 767(33.32) | |||
淋巴细胞计数( | 1.9±0.6 | 2.2±0.7 | 19.815 | <0.001 | NAFLD组 | 725(30.85) | 523(22.72) | |||
血小板计数( | 223.2±59.4 | 237.3±64.9 | 7.740 | <0.001 | MAFLD组 | 444(18.89) | 1 012(43.96) | |||
NLR( | 1.84±0.75 | 1.95±0.99 | 20.166 | <0.001 |
Figure 4 Multivariate regression tree analysis of the association of sex,BMI,triacylglycerol,and fasting blood glucose with monocyte to high-density lipoprotein cholesterol ratio
[1] |
|
[2] |
|
[3] |
|
[4] |
中华人民共和国卫生部疾病控制司. 血吸虫病防治手册[M]. 3版. 上海:上海科学技术出版社,2000.
|
[5] |
李岳生. 血吸虫病诊断与治疗[M]. 北京:人民卫生出版社,2006.
|
[6] |
中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)[J]. 中华内分泌代谢杂志,2018,34(7):549-554. DOI:10.3760/cma.j.issn.1000-6699.2018.07.004.
|
[7] |
|
[8] |
中华医学会,中华医学会杂志社,中华医学会消化病学分会,等. 酒精性肝病基层诊疗指南(2019年)[J]. 中华全科医师杂志,2020,19(11):990-996. DOI:10.3760/cma.j.cn114798-20200812-00898.
|
[9] | |
[10] |
中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等.中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,24(1):24-56. DOI:10.3969/j.issn.1007-5410.2019.01.002.
|
[11] |
中华医学会,中华医学会杂志社,中华医学会全科医学分会,等. 血脂异常基层诊疗指南(2019年)[J]. 中华全科医师杂志,2019,18(5):406-416. DOI:10.3760/cma.j.issn.1671-7368.2019.05.003.
|
[12] |
|
[13] |
张玄娥,顾蕾,张晓燕,等. 上海杨浦中老年社区人群内脏脂肪指数和脂质蓄积指数与血尿酸的相关性[J]. 同济大学学报(医学版),2020,41(2):185-191. DOI:10.16118/j.1008-0392.2020.02.008.
|
[14] |
李礼,王凤荣. 冠状动脉Gensini评分、血浆致动脉硬化指数与不稳定型心绞痛中医证型相关性的研究进展[J]. 中国民间疗法,2020,28(24):113-115. DOI:10.19621/j.cnki.11-3555/r.2020.2445.
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
唐任宽. 慢性炎症状态下脂质代谢紊乱及肝脏、主动脉损害的分子机制[D]. 重庆:重庆医科大学,2008.
|
[20] |
顾伟根,冯静亚. 超重和肥胖人群非酒精性脂肪肝的流行现状及相关危险因素分析[J]. 甘肃医药,2015,34(2):112-115.
|
[21] |
赵波,胡来明,李小莉. 血脂及炎症指标在非酒精性脂肪肝合并颈动脉粥样硬化患者中的改变[J]. 胃肠病学和肝病学杂志,2017,26(12):1406-1408. DOI:10.3969/j.issn.1006-5709.2017.12.020.
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[1] | WANG Lina, GAO Pengfei, CAO Fan, GE Ying, YAN Wei, HE Daikun. Analysis of the Prevalence and Influencing Factors of Non-alcoholic Fatty Liver Disease in Different Gender Groups [J]. Chinese General Practice, 2023, 26(33): 4143-4151. |
[2] | ZHOU Xiaoqi, LIU Xinhui, ZHANG Wei, LI Changfeng, YAN Yaqiong. Association of Alanine Transaminase and Aspartate Aminotransferase/Alanine Transaminase Ratio with Type 2 Diabetes and Metabolic Syndrome in the Elderly [J]. Chinese General Practice, 2023, 26(29): 3645-3649. |
[3] | GU Yunjie, SONG Jing, YIN Jun. Clinical Study on Low-carbon Diet for Endogenous-insulin-deficient Diabetes Patients [J]. Chinese General Practice, 2023, 26(26): 3308-3313. |
[4] | KONG Dexian, XING Yuling, SUN Wenwen, ZHANG Zhimin, ZHOU Fei, MA Huijuan. Correlation between Estimated Glucose Disposal Rate and Metabolism-associated Fatty Liver Disease in Type 2 Diabetes [J]. Chinese General Practice, 2023, 26(26): 3252-3258. |
[5] | YUAN Xianxian, WANG Jia, ZHANG Kexin, YANG Ruihua, ZHENG Wei, LI Guanghui. Association between Blood Lipid Levels and Macrosomia in Pregnant Women with Different Pre-pregnancy Body Mass Index [J]. Chinese General Practice, 2023, 26(24): 2973-2979. |
[6] | HE Rong, ZHANG Li, LI Peng, ZHANG Xiaoling, ZHANG Guo, ZANG Yiran, WU Shouling, SUN Lixia. Immediate Effects of Aerobic Exercise on Arterial Stiffness in a Male Population with Different Blood Glucose Levels [J]. Chinese General Practice, 2023, 26(24): 2997-3004. |
[7] | GAO Zhe, DUAN Kaixin, LYU Xiuqin, MA Huijuan, ZHANG Zhimei, SONG Guangyao. Mechanism of Glucagon-like Peptide-1 Receptor Agonist Improving Liver Lipid Deposition in a Rat Model of Insulin Resistance Induced by High-fructose Diet [J]. Chinese General Practice, 2023, 26(21): 2639-2646. |
[8] | ZHOU Shiyu, CHEN Shaolin, DENG Renli, DAI Mi, LIU Tao, TIAN Kunming. The Association and Predictive Value of Lipid Ratios to Metabolic Syndrome: a Multistage Cross-sectional Study [J]. Chinese General Practice, 2023, 26(21): 2589-2596. |
[9] | ZHANG Zhuoran, YU Changhe, AN Yi, HE Xin, GUO Yi, DENG Jinyan, LI Yue, HAN Deng, PI Shanshan, HE Junzhi, CHEN Yue, YE Yong'an, DU Hongbo. Quality Assessment and Recommendations of Clinical Guidelines and Consensuses on Non-alcoholic Fatty Liver Disease: a Comparative Study [J]. Chinese General Practice, 2023, 26(20): 2439-2446. |
[10] | LYU Cuicui, WANG Qihua, XIAO Yao, JIANG Jing, LIU Xiaoyun. Impact of Elevated Fasting Blood Glucose on Urodynamic Parameters in Patients with Benign Prostatic Hyperplasia [J]. Chinese General Practice, 2023, 26(18): 2223-2226. |
[11] | LUO Rong, WANG Yu, MIAO Afeng, WU Xiaoke. Influencing Factors of Insulin Resistance in Polycystic Ovary Syndrome Patients with Normal Body Mass Index [J]. Chinese General Practice, 2023, 26(17): 2102-2107. |
[12] | ZHOU Yi, GAO Yunyi, LI Sheyu, TONG Nanwei, CHEN Min, LI Dajiang, JIANG Yan, ZHANG Weiyi, CHEN Xiangjun. Performance Surveillance of Active Blood Glucose Management during Hospitalization Based on the PDCA Cycle: a Practical Study [J]. Chinese General Practice, 2023, 26(15): 1811-1816. |
[13] | CHEN Xiangyang, LI Sheyu. Glycemic Management for Hospitalized Patients with Diabetes in Non-endocrine Wards [J]. Chinese General Practice, 2023, 26(15): 1799-1803. |
[14] | WANG Lingxiao, DONG Rongna, ZHOU Bing, GUO Lina, LI Jing. Analysis of the Effect of Human-computer Interaction Intelligent Management on Blood Glucose Control in New-onset Type 2 Diabetes Mellitus Patients [J]. Chinese General Practice, 2023, 26(15): 1817-1823. |
[15] | YANG Bei, HAN Lin, WANG Yin, CHENG Kangyao. Effectiveness of Continuous Subcutaneous Insulin Injection in Type 2 Diabetes in Older Adults: a Meta-analysis and Trial Sequential Analysis [J]. Chinese General Practice, 2023, 26(15): 1892-1901. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||